NATERA INC (NTRA) Fundamental Analysis & Valuation

NASDAQ:NTRA • US6323071042

Current stock price

207.98 USD
+4.77 (+2.35%)
At close:
207.98 USD
0 (0%)
After Hours:

This NTRA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. NTRA Profitability Analysis

1.1 Basic Checks

  • NTRA had negative earnings in the past year.
  • In the past year NTRA had a positive cash flow from operations.
  • NTRA had negative earnings in each of the past 5 years.
  • In multiple years NTRA reported negative operating cash flow during the last 5 years.
NTRA Yearly Net Income VS EBIT VS OCF VS FCFNTRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M -400M

1.2 Ratios

  • NTRA's Return On Assets of -8.68% is amongst the best of the industry. NTRA outperforms 83.37% of its industry peers.
  • NTRA has a better Return On Equity (-12.16%) than 85.30% of its industry peers.
Industry RankSector Rank
ROA -8.68%
ROE -12.16%
ROIC N/A
ROA(3y)-16.77%
ROA(5y)-25.55%
ROE(3y)-28.3%
ROE(5y)-46.95%
ROIC(3y)N/A
ROIC(5y)N/A
NTRA Yearly ROA, ROE, ROICNTRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400 -500

1.3 Margins

  • NTRA has a better Gross Margin (64.75%) than 78.72% of its industry peers.
  • NTRA's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for NTRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.75%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.42%
GM growth 5Y6.2%
NTRA Yearly Profit, Operating, Gross MarginsNTRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. NTRA Health Analysis

2.1 Basic Checks

  • NTRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, NTRA has more shares outstanding
  • The number of shares outstanding for NTRA has been increased compared to 5 years ago.
  • The debt/assets ratio for NTRA has been reduced compared to a year ago.
NTRA Yearly Shares OutstandingNTRA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
NTRA Yearly Total Debt VS Total AssetsNTRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • NTRA has an Altman-Z score of 24.64. This indicates that NTRA is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 24.64, NTRA belongs to the best of the industry, outperforming 91.30% of the companies in the same industry.
  • NTRA has a debt to FCF ratio of 1.06. This is a very positive value and a sign of high solvency as it would only need 1.06 years to pay back of all of its debts.
  • NTRA's Debt to FCF ratio of 1.06 is amongst the best of the industry. NTRA outperforms 94.20% of its industry peers.
  • A Debt/Equity ratio of 0.05 indicates that NTRA is not too dependend on debt financing.
  • NTRA has a Debt to Equity ratio (0.05) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF 1.06
Altman-Z 24.64
ROIC/WACCN/A
WACC9.21%
NTRA Yearly LT Debt VS Equity VS FCFNTRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 3.39 indicates that NTRA has no problem at all paying its short term obligations.
  • With a Current ratio value of 3.39, NTRA perfoms like the industry average, outperforming 41.78% of the companies in the same industry.
  • A Quick Ratio of 3.24 indicates that NTRA has no problem at all paying its short term obligations.
  • NTRA has a Quick ratio (3.24) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.39
Quick Ratio 3.24
NTRA Yearly Current Assets VS Current LiabilitesNTRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. NTRA Growth Analysis

3.1 Past

  • NTRA shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.65%.
  • NTRA shows a strong growth in Revenue. In the last year, the Revenue has grown by 35.90%.
  • Measured over the past years, NTRA shows a very strong growth in Revenue. The Revenue has been growing by 42.61% on average per year.
EPS 1Y (TTM)0.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%187.8%
Revenue 1Y (TTM)35.9%
Revenue growth 3Y41.14%
Revenue growth 5Y42.61%
Sales Q2Q%39.78%

3.2 Future

  • NTRA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 37.27% yearly.
  • NTRA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.55% yearly.
EPS Next Y-25.06%
EPS Next 2Y32.85%
EPS Next 3Y40.11%
EPS Next 5Y37.27%
Revenue Next Year19.68%
Revenue Next 2Y19.84%
Revenue Next 3Y19.71%
Revenue Next 5Y17.55%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
NTRA Yearly Revenue VS EstimatesNTRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
NTRA Yearly EPS VS EstimatesNTRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 5 -5 10

More info and screens

Find the best growth stocksShow best growing peers

2

4. NTRA Valuation Analysis

4.1 Price/Earnings Ratio

  • NTRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year NTRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NTRA Price Earnings VS Forward Price EarningsNTRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of NTRA indicates a rather cheap valuation: NTRA is cheaper than 88.97% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 387.28
EV/EBITDA N/A
NTRA Per share dataNTRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • A more expensive valuation may be justified as NTRA's earnings are expected to grow with 40.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.85%
EPS Next 3Y40.11%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NTRA Dividend Analysis

5.1 Amount

  • NTRA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NTRA Fundamentals: All Metrics, Ratios and Statistics

NATERA INC

NASDAQ:NTRA (4/2/2026, 8:00:02 PM)

After market: 207.98 0 (0%)

207.98

+4.77 (+2.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners93.51%
Inst Owner Change0.51%
Ins Owners3.04%
Ins Owner Change0.44%
Market Cap29.48B
Revenue(TTM)2.31B
Net Income(TTM)-208.16M
Analysts85
Price Target258.63 (24.35%)
Short Float %2.42%
Short Ratio2.8
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)50.47%
Min EPS beat(2)-68.19%
Max EPS beat(2)169.13%
EPS beat(4)2
Avg EPS beat(4)26.55%
Min EPS beat(4)-68.19%
Max EPS beat(4)169.13%
EPS beat(8)5
Avg EPS beat(8)29.82%
EPS beat(12)8
Avg EPS beat(12)21.96%
EPS beat(16)12
Avg EPS beat(16)18.12%
Revenue beat(2)2
Avg Revenue beat(2)11.68%
Min Revenue beat(2)10.13%
Max Revenue beat(2)13.23%
Revenue beat(4)4
Avg Revenue beat(4)11.53%
Min Revenue beat(4)10.13%
Max Revenue beat(4)13.23%
Revenue beat(8)8
Avg Revenue beat(8)13.31%
Revenue beat(12)12
Avg Revenue beat(12)10.39%
Revenue beat(16)14
Avg Revenue beat(16)8.14%
PT rev (1m)-1.43%
PT rev (3m)5.75%
EPS NQ rev (1m)0.28%
EPS NQ rev (3m)2.25%
EPS NY rev (1m)1.17%
EPS NY rev (3m)1.03%
Revenue NQ rev (1m)0.83%
Revenue NQ rev (3m)2.04%
Revenue NY rev (1m)2.56%
Revenue NY rev (3m)3.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.78
P/FCF 387.28
P/OCF 136.91
P/B 17.21
P/tB 24.61
EV/EBITDA N/A
EPS(TTM)-1.52
EYN/A
EPS(NY)-1.9
Fwd EYN/A
FCF(TTM)0.54
FCFY0.26%
OCF(TTM)1.52
OCFY0.73%
SpS16.27
BVpS12.08
TBVpS8.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.68%
ROE -12.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.75%
FCFM 3.3%
ROA(3y)-16.77%
ROA(5y)-25.55%
ROE(3y)-28.3%
ROE(5y)-46.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.42%
GM growth 5Y6.2%
F-Score5
Asset Turnover0.96
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF 1.06
Debt/EBITDA N/A
Cap/Depr 320.09%
Cap/Sales 6.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.39
Quick Ratio 3.24
Altman-Z 24.64
F-Score5
WACC9.21%
ROIC/WACCN/A
Cap/Depr(3y)243.71%
Cap/Depr(5y)291.51%
Cap/Sales(3y)4.73%
Cap/Sales(5y)5.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%187.8%
EPS Next Y-25.06%
EPS Next 2Y32.85%
EPS Next 3Y40.11%
EPS Next 5Y37.27%
Revenue 1Y (TTM)35.9%
Revenue growth 3Y41.14%
Revenue growth 5Y42.61%
Sales Q2Q%39.78%
Revenue Next Year19.68%
Revenue Next 2Y19.84%
Revenue Next 3Y19.71%
Revenue Next 5Y17.55%
EBIT growth 1Y-37.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year34.47%
EBIT Next 3Y41.8%
EBIT Next 5Y29.98%
FCF growth 1Y29.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.7%
OCF growth 3YN/A
OCF growth 5YN/A

NATERA INC / NTRA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of NATERA INC (NTRA) stock?

ChartMill assigns a fundamental rating of 4 / 10 to NTRA.


What is the valuation status of NATERA INC (NTRA) stock?

ChartMill assigns a valuation rating of 2 / 10 to NATERA INC (NTRA). This can be considered as Overvalued.


Can you provide the profitability details for NATERA INC?

NATERA INC (NTRA) has a profitability rating of 3 / 10.


What is the expected EPS growth for NATERA INC (NTRA) stock?

The Earnings per Share (EPS) of NATERA INC (NTRA) is expected to decline by -25.06% in the next year.